# Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

Source: https://onco.cc/trials/nct07648264/  
OnCo record `nct07648264` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of IgPro20 in advanced solid tumours, run by CSL Behring, now recruiting.

## Summary

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies is a phase 3 interventional study registered as NCT07648264 by CSL Behring, with 63 participants planned, started 2026-09-11 and due to reach its primary completion in 2029-03-13. Interventions recorded: IgPro20.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07648264
- Phase: 3
- Setting: A Phase 3, Prospective, Open-label, Multicenter, Single-arm Study to Investigate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Subjects With Secondary Immune Deficiency Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Sponsor: CSL Behring
- Enrolled: 63

## Sources

- ClinicalTrials.gov NCT07648264: https://clinicaltrials.gov/study/NCT07648264

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [CSL Limited](https://onco.cc/companies/csl/)

---
JSON: https://onco.cc/api/v1/entities/nct07648264.json